Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price ...
Promising Clinical Developments in Rocket Pharmaceuticals Justify Buy Rating and $52 Target Price
Rocket Pharmaceuticals (RCKT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum ...
The Motley Fool16h
Lockheed Martin Just Lost a Multibillion-Dollar Deal -- but All Hope Is Not Lost
when an interview with Vector Space Systems' then-CEO Jim Cantrell revealed just how cheap small satellites had become.